Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 87 entries
Sorted by: Best Match Show Resources per page
Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy.

Case reports in oncological medicine

Zyczynski LE, McHugh JB, Gribbin TE, Schuetze SM.
PMID: 26266067
Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22.

A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She...

Cite
Zyczynski LE, McHugh JB, Gribbin TE, et al. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479doi: 10.1155/2015/107479.
Zyczynski, L. E., McHugh, J. B., Gribbin, T. E., & Schuetze, S. M. (2015). Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case reports in oncological medicine, 2015107479. https://doi.org/10.1155/2015/107479
Zyczynski, Laura E, et al. "Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy." Case reports in oncological medicine vol. 2015 (2015): 107479. doi: https://doi.org/10.1155/2015/107479
Zyczynski LE, McHugh JB, Gribbin TE, Schuetze SM. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22. PMID: 26266067; PMCID: PMC4525456.
Copy Download .nbib Format: NLM
Effects of benzoic acid (VevoVitall®) on the performance and jejunal digestive physiology in young pigs.

Journal of animal science and biotechnology

Diao H, Gao Z, Yu B, Zheng P, He J, Yu J, Huang Z, Chen D, Mao X.
PMID: 27239300
J Anim Sci Biotechnol. 2016 May 28;7:32. doi: 10.1186/s40104-016-0091-y. eCollection 2016.

BACKGROUND: As a organic acid, benzoic acid has become one of the most important alternatives for antibiotics, and its beneficial effect on performance in animals has been proven for a decade. However, knowledge of the effects of benzoic acid...

Cite
Diao H, Gao Z, Yu B, et al. Effects of benzoic acid (VevoVitall®) on the performance and jejunal digestive physiology in young pigs. J Anim Sci Biotechnol. 2016;7:32doi: 10.1186/s40104-016-0091-y.
Diao, H., Gao, Z., Yu, B., Zheng, P., He, J., Yu, J., Huang, Z., Chen, D., & Mao, X. (2016). Effects of benzoic acid (VevoVitall®) on the performance and jejunal digestive physiology in young pigs. Journal of animal science and biotechnology, 732. https://doi.org/10.1186/s40104-016-0091-y
Diao, Hui, et al. "Effects of benzoic acid (VevoVitall®) on the performance and jejunal digestive physiology in young pigs." Journal of animal science and biotechnology vol. 7 (2016): 32. doi: https://doi.org/10.1186/s40104-016-0091-y
Diao H, Gao Z, Yu B, Zheng P, He J, Yu J, Huang Z, Chen D, Mao X. Effects of benzoic acid (VevoVitall®) on the performance and jejunal digestive physiology in young pigs. J Anim Sci Biotechnol. 2016 May 28;7:32. doi: 10.1186/s40104-016-0091-y. eCollection 2016. PMID: 27239300; PMCID: PMC4884408.
Copy Download .nbib Format: NLM
New advances in the molecular and cellular biology of the small intestine.

Current opinion in gastroenterology

Walters JR.
PMID: 17033281
Curr Opin Gastroenterol. 2002 Mar;18(2):161-7. doi: 10.1097/00001574-200203000-00002.

Research into the structure and function of the small intestinal mucosa is becoming increasingly focused on the molecular and cellular biology of this fascinating tissue. There is a growing understanding of the factors determining the expression of specific genes...

Cite
Walters JR. New advances in the molecular and cellular biology of the small intestine. Curr Opin Gastroenterol. 2002;18(2):161-7doi: 10.1097/00001574-200203000-00002.
Walters, J. R. (2002). New advances in the molecular and cellular biology of the small intestine. Current opinion in gastroenterology, 18(2), 161-7. https://doi.org/10.1097/00001574-200203000-00002
Walters, Julian R F. "New advances in the molecular and cellular biology of the small intestine." Current opinion in gastroenterology vol. 18,2 (2002): 161-7. doi: https://doi.org/10.1097/00001574-200203000-00002
Walters JR. New advances in the molecular and cellular biology of the small intestine. Curr Opin Gastroenterol. 2002 Mar;18(2):161-7. doi: 10.1097/00001574-200203000-00002. PMID: 17033281.
Copy Download .nbib Format: NLM
Short bowel syndrome.

Current treatment options in gastroenterology

Parekh NR, Steiger E.
PMID: 17298760
Curr Treat Options Gastroenterol. 2007 Feb;10(1):10-23. doi: 10.1007/s11938-007-0052-9.

Treatment of short bowel syndrome (SBS) is often a difficult endeavor due to the high variability among patients with SBS in regard to remaining anatomical structure and functional capacity. Research efforts to substantiate the use of existing therapies in...

Cite
Parekh NR, Steiger E. Short bowel syndrome. Curr Treat Options Gastroenterol. 2007;10(1):10-23doi: 10.1007/s11938-007-0052-9.
Parekh, N. R., & Steiger, E. (2007). Short bowel syndrome. Current treatment options in gastroenterology, 10(1), 10-23. https://doi.org/10.1007/s11938-007-0052-9
Parekh, Neha R, and Steiger, Ezra. "Short bowel syndrome." Current treatment options in gastroenterology vol. 10,1 (2007): 10-23. doi: https://doi.org/10.1007/s11938-007-0052-9
Parekh NR, Steiger E. Short bowel syndrome. Curr Treat Options Gastroenterol. 2007 Feb;10(1):10-23. doi: 10.1007/s11938-007-0052-9. PMID: 17298760.
Copy Download .nbib Format: NLM
The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing.

Gastroenterology research and practice

Redstone HA, Buie WD, Hart DA, Wallace L, Hornby PJ, Sague S, Holst JJ, Sigalet DL.
PMID: 20953406
Gastroenterol Res Pract. 2010;2010. doi: 10.1155/2010/672453. Epub 2010 Oct 04.

Background. Glucagon-like peptide 2 (GLP-2) is an intestinal specific trophic hormone, with therapeutic potential; the effects on intestinal healing are unknown. We used a rat model of colonic healing, under normoxic, and stress (hypoxic) conditions to examine the effect...

Cite
Redstone HA, Buie WD, Hart DA, et al. The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterol Res Pract. 2010;2010doi: 10.1155/2010/672453.
Redstone, H. A., Buie, W. D., Hart, D. A., Wallace, L., Hornby, P. J., Sague, S., Holst, J. J., & Sigalet, D. L. (2010). The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterology research and practice, 2010. https://doi.org/10.1155/2010/672453
Redstone, Heather A, et al. "The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing." Gastroenterology research and practice vol. 2010 (2010). doi: https://doi.org/10.1155/2010/672453
Redstone HA, Buie WD, Hart DA, Wallace L, Hornby PJ, Sague S, Holst JJ, Sigalet DL. The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterol Res Pract. 2010;2010. doi: 10.1155/2010/672453. Epub 2010 Oct 04. PMID: 20953406; PMCID: PMC2952794.
Copy Download .nbib Format: NLM
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Gastroenterology research and practice

Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB.
PMID: 19707516
Gastroenterol Res Pract. 2009;2009:616054. doi: 10.1155/2009/616054. Epub 2009 Aug 20.

BACKGROUND AND AIMS: In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years.METHODS: GLP-2, 400...

Cite
Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009;2009:616054doi: 10.1155/2009/616054.
Jeppesen, P. B., Lund, P., Gottschalck, I. B., Nielsen, H. B., Holst, J. J., Mortensen, J., Poulsen, S. S., Quistorff, B., & Mortensen, P. B. (2009). Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterology research and practice, 2009616054. https://doi.org/10.1155/2009/616054
Jeppesen, P B, et al. "Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function." Gastroenterology research and practice vol. 2009 (2009): 616054. doi: https://doi.org/10.1155/2009/616054
Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009;2009:616054. doi: 10.1155/2009/616054. Epub 2009 Aug 20. PMID: 19707516; PMCID: PMC2729387.
Copy Download .nbib Format: NLM
Glucagon-like Peptide 2.

Trends in endocrinology and metabolism: TEM

Drucker DJ.
PMID: 10322410
Trends Endocrinol Metab. 1999 May;10(4):153-156. doi: 10.1016/s1043-2760(98)00136-2.

Glucagon-like peptide 2 (GLP-2) is secreted in a nutrient-dependent manner from enteroendocrine cells throughout the gastrointestinal tract and is trophic to the intestinal epithelial mucosa. GLP-2 acts via stimulation of crypt cell proliferation and inhibition of cell death. GLP-2...

Cite
Drucker DJ. Glucagon-like Peptide 2. Trends Endocrinol Metab. 1999;10(4):153-156doi: 10.1016/s1043-2760(98)00136-2.
Drucker, D. J. (1999). Glucagon-like Peptide 2. Trends in endocrinology and metabolism: TEM, 10(4), 153-156. https://doi.org/10.1016/s1043-2760(98)00136-2
Drucker. "Glucagon-like Peptide 2." Trends in endocrinology and metabolism: TEM vol. 10,4 (1999): 153-156. doi: https://doi.org/10.1016/s1043-2760(98)00136-2
Drucker DJ. Glucagon-like Peptide 2. Trends Endocrinol Metab. 1999 May;10(4):153-156. doi: 10.1016/s1043-2760(98)00136-2. PMID: 10322410.
Copy Download .nbib Format: NLM
Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na.

Frontiers in nutrition

Moran AW, Al-Rammahi MA, Batchelor DJ, Bravo DM, Shirazi-Beechey SP.
PMID: 30416998
Front Nutr. 2018 Oct 26;5:101. doi: 10.3389/fnut.2018.00101. eCollection 2018.

The Na

Cite
Moran AW, Al-Rammahi MA, Batchelor DJ, et al. Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na. Front Nutr. 2018;5:101doi: 10.3389/fnut.2018.00101.
Moran, A. W., Al-Rammahi, M. A., Batchelor, D. J., Bravo, D. M., & Shirazi-Beechey, S. P. (2018). Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na. Frontiers in nutrition, 5101. https://doi.org/10.3389/fnut.2018.00101
Moran, Andrew W, et al. "Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na." Frontiers in nutrition vol. 5 (2018): 101. doi: https://doi.org/10.3389/fnut.2018.00101
Moran AW, Al-Rammahi MA, Batchelor DJ, Bravo DM, Shirazi-Beechey SP. Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na. Front Nutr. 2018 Oct 26;5:101. doi: 10.3389/fnut.2018.00101. eCollection 2018. PMID: 30416998; PMCID: PMC6212479.
Copy Download .nbib Format: NLM
GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength.

Bone reports

Gobron B, Bouvard B, Legrand E, Chappard D, Mabilleau G.
PMID: 32071954
Bone Rep. 2020 Feb 05;12:100251. doi: 10.1016/j.bonr.2020.100251. eCollection 2020 Jun.

Osteoporosis and bone fragility are progressing worldwide. Previous published literature reported a possible beneficial role of gut hormones, and especially glucagon-like peptide-2 (GLP-2), in modulating bone remodeling. As now (Gly

Cite
Gobron B, Bouvard B, Legrand E, et al. GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength. Bone Rep. 2020;12:100251doi: 10.1016/j.bonr.2020.100251.
Gobron, B., Bouvard, B., Legrand, E., Chappard, D., & Mabilleau, G. (2020). GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength. Bone reports, 12100251. https://doi.org/10.1016/j.bonr.2020.100251
Gobron, B, et al. "GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength." Bone reports vol. 12 (2020): 100251. doi: https://doi.org/10.1016/j.bonr.2020.100251
Gobron B, Bouvard B, Legrand E, Chappard D, Mabilleau G. GLP-2 administration in ovariectomized mice enhances collagen maturity but did not improve bone strength. Bone Rep. 2020 Feb 05;12:100251. doi: 10.1016/j.bonr.2020.100251. eCollection 2020 Jun. PMID: 32071954; PMCID: PMC7013338.
Copy Download .nbib Format: NLM
The roles of the glucagon-like peptide-2 and the serum TGF-β1 levels in the intestinal barrier and immune functions in rats with obstructive jaundice.

American journal of translational research

Wang C, Fan W, Feng X, Zhang Y, Liu C, Liu Z.
PMID: 34650714
Am J Transl Res. 2021 Sep 15;13(9):10449-10458. eCollection 2021.

OBJECTIVE: To determine the mechanisms by which glucagon-like peptide-2 (GLP-2) impacts the intestinal barrier function, the immune function, and the serum transforming growth factor-β1 (TGF-β1) levels in rats with obstructive jaundice.METHODS: Overall, 72 SPF-grade healthy Wistar rats were randomly...

Cite
Wang C, Fan W, Feng X, et al. The roles of the glucagon-like peptide-2 and the serum TGF-β1 levels in the intestinal barrier and immune functions in rats with obstructive jaundice. Am J Transl Res. 2021;13(9):10449-10458
Wang, C., Fan, W., Feng, X., Zhang, Y., Liu, C., & Liu, Z. (2021). The roles of the glucagon-like peptide-2 and the serum TGF-β1 levels in the intestinal barrier and immune functions in rats with obstructive jaundice. American journal of translational research, 13(9), 10449-10458.
Wang, Changyuan, et al. "The roles of the glucagon-like peptide-2 and the serum TGF-β1 levels in the intestinal barrier and immune functions in rats with obstructive jaundice." American journal of translational research vol. 13,9 (2021): 10449-10458.
Wang C, Fan W, Feng X, Zhang Y, Liu C, Liu Z. The roles of the glucagon-like peptide-2 and the serum TGF-β1 levels in the intestinal barrier and immune functions in rats with obstructive jaundice. Am J Transl Res. 2021 Sep 15;13(9):10449-10458. eCollection 2021. PMID: 34650714; PMCID: PMC8506993.
Copy Download .nbib Format: NLM
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome.

ACS pharmacology & translational science

Drucker DJ.
PMID: 32219218
ACS Pharmacol Transl Sci. 2019 Mar 01;2(2):134-142. doi: 10.1021/acsptsci.9b00016. eCollection 2019 Apr 12.

The proglucagon gene encodes multiple structurally related peptides with overlapping actions promoting the absorption and assimilation of ingested energy. Notably, glucagon has been developed pharmaceutically to treat hypoglycemia, and glucagon-like peptide-1 (GLP-1) receptor agonists are used for the therapy...

Cite
Drucker DJ. The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacol Transl Sci. 2019;2(2):134-142doi: 10.1021/acsptsci.9b00016.
Drucker, D. J. (2019). The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS pharmacology & translational science, 2(2), 134-142. https://doi.org/10.1021/acsptsci.9b00016
Drucker, Daniel J. "The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome." ACS pharmacology & translational science vol. 2,2 (2019): 134-142. doi: https://doi.org/10.1021/acsptsci.9b00016
Drucker DJ. The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacol Transl Sci. 2019 Mar 01;2(2):134-142. doi: 10.1021/acsptsci.9b00016. eCollection 2019 Apr 12. PMID: 32219218; PMCID: PMC7088900.
Copy Download .nbib Format: NLM
Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome".

The Journal of pharmacology and experimental therapeutics

Skarbaliene J, Larsen BD, Berner-Hansen M, Steensberg A.
PMID: 34039655
J Pharmacol Exp Ther. 2021 Jun;377(3):369. doi: 10.1124/jpet.120.000426.

No abstract available.

Cite
Skarbaliene J, Larsen BD, Berner-Hansen M, et al. Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome". J Pharmacol Exp Ther. 2021;377(3):369doi: 10.1124/jpet.120.000426.
Skarbaliene, J., Larsen, B. D., Berner-Hansen, M., & Steensberg, A. (2021). Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome". The Journal of pharmacology and experimental therapeutics, 377(3), 369. https://doi.org/10.1124/jpet.120.000426
Skarbaliene, Jolanta, et al. "Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome"." The Journal of pharmacology and experimental therapeutics vol. 377,3 (2021): 369. doi: https://doi.org/10.1124/jpet.120.000426
Skarbaliene J, Larsen BD, Berner-Hansen M, Steensberg A. Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome". J Pharmacol Exp Ther. 2021 Jun;377(3):369. doi: 10.1124/jpet.120.000426. PMID: 34039655.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 87 entries